Abstract. The epidermal growth factor receptor (EGFR) is often amplified in glioma, with the most common extracellular domain mutation being EGFR variant III (EGFRvIII). Abnormal EGFRvIII signaling has been shown to be important in driving tumor progression. Centrosomal protein 55 (CEP55), a member of the centrosomal relative proteins family, participates cytokinesis in the cell cycle. It exists in a few normal tissues and various tumor cells. The expression and function of CEP55 in human glioma cells need to investigate. In this study, the expression of CEP55 was detected in 40 cases of glioma tissues and 10 cases of non-tumor brain tissue. The proliferation of glioblastoma U251 cells was analyzed after transfection with EGFRvIII and CEP55 siRNA. We found that the expression of CEP55 was increased significantly in the glioma tissues than in normal brain tissue. The proliferation of U251 cells increased remarkably after transfection with EGFRvIII. Knockdown of CEP55 inhibited proliferation of U251 cells and was able to eliminate the effect of promoting proliferation induced by EGFRvIII in U251 cells. CEP55 played a key role in the proliferation of glioma cells and mediated EGFRvIII-stimulated proliferation in glioma cells. CEP55 might be a novel molecular therapeutic target in patients with gliomas expressing EGFRvIII.
Introduction
Gliomas are the most frequent type of malignant tumor in central nervous system, leading to significant mortality worldwide annually (1, 2) . It was classified into low-grade gliomas (grade II, e.g., infiltrative astrocytomas and oligodendrogliomas) and high-grade gliomas (grade III and IV, e.g., anaplastic gliomas and glioblastomas) according to the World Health Organization grading system (3). The current therapeutic strategy to glioma consists of surgical resection, radiotherapy, chemotherapy and antiangiogenesis. However, the prognosis of the patients with glioma is still poor in spite of these interventions. Only one third of patients with glioblastoma (GBM) survival for a year and the 5-year survival rate for grade III gliomas is 27% (4) . The epidermal growth factor receptor (EGFR) plays a key role in proliferation and pathogenesis of multiple cancer types. Expression of EGFR correlates with poor prognosis and radioresistance in glioma (5) .
EGFR amplification and overexpression have been identified in ~50% of GBM patients. EGFR overexpression is often accompanied by the expression of a mutant EGFR named as EGFRvIII (EGFR type III, ΔEGFR), which is expressed in 30% of GBM tumors (6, 7) . EGFRvIII is generated from a genomic deletion involving exons 2-7 of the EGFR gene, which results in deletion of the extracellular ligand-binding domain. It is unable to bind ligand, yet constitutively activated in a ligand-independent manner leading to overproliferation, survival, resistance to treatment and invasiveness of GBM cells (8, 9) . Both of the classical subtypes classified by the TCGA working group and the EM subgroup classified by the CGGA working group showed that the characteristics of EGFR activation associated with amplification and mutation displayed the worst prognosis (10) (11) (12) .
Centrosomal protein 55 (CEP55) is the latest found member in the centrosomal relative protein family, which participates in the regulation of the cell cycle. CEP55 is located in the centrosome in interphase cells and is recruited into the midbody during cytokinesis (13) . In addition, CEP55 is required for midbody structure and the completion of cytokinesis at the terminal stage (14) . Overexpressing of CEP55 Overexpression of centrosomal protein 55 regulates the proliferation of glioma cell and mediates proliferation promoted by EGFRvIII in glioblastoma U251 cells were found in several human tumors and various tumor cell lines (15) (16) (17) . However, the relationship between EGFRvIII and CEP55 in proliferation regulation of glioma cells and the effect of CEP55 on these malignant features of GBM is poorly understood. Therefore, we detected the expression of CEP55 in human glioma tissues and investigated the proliferation of glioblastoma U251 cells after transfected with EGFRvIII and CEP55 siRNA. Western-blot analysis. For western blot analyses, protein was harvested from cells plated to 70-80% confluence. Cell lysates were prepared using a RIPA buffer (25 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate; pH 7.6). Protease inhibitors were added prior to use. The protein extracts were loaded, size-fractionated by SDS-polyacrylamide gel electrophoresis and transferred to PVDF membranes (Bio-Rad Laboratories, Inc., Hercules, CA, USA). After blocking, the membranes were incubated with the specific first antibodies (Abcam, Cambridge, UK) in dilution buffer at 4˚C overnight. The blots were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5,000, anti-rabbit/anti-mouse; Boster Biological Technology Co., Ltd., Wuhan, China) at room temperature for 2 h and then chemiluminescence signals were detected using a UVI gel imaging system camera.
Materials and methods

Tissue
Quantitative real-time PCR. Total RNA was extracted from frozen tissues and cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions and was reverse transcribed into cDNA using PrimeScript RT reagent (Takara Bio Inc., Shiga, Japan). The reaction system (20 µl) contained the corresponding cDNA. The CEP55 primers used in quantitative real-time PCR were as follows: forward primer of 5'-TTG GAA CAA CAG ATG C AG GC-3' and reverse primer of 5'-GAG TGC AGC AGT GGG A CT TT-3'. GAP DH, used as an internal control, was amplified with forward primer 5'-TGG ACT CCA CGA CGT ACT CAG-3' and reverse primer 5'-CGG GAA GCT TGT CAT CAA TGG AA-3'. All procedures were performed in triplicate.
RNAi and transfection.
To further identify the role of CEP55 in tumor and the relationship of CEP55 and EGFRvIII, the CEP55 knockdown lentiviral vector (siCEP55) was constructed (Shanghai GeneChem Co., Ltd., Shanghai, China). A GFP lentiviral vector was used as negative control (NC). The day before transfection, cells were seeded in 24-well plates at a density of 50,000 cells/well. The lentiviruses were transfected according to the manufacturer's instruction with MOI=10, and stably transfection cells were selected by puromycin (6 µg/ml). All lentiviral vectors expressed GFP and Puromycin, which enabled us to select stably transfection cells. The siRNA sequences are as following: 5'-GTG GGA AAG GAA AGC TGA C-3'. The high expression of EGFRvIII lentiviral vector was also constructed (Shanghai GeneChem Co., Ltd.). The sequences resulted from NCBI. The following are the NCBI reference sequence: NM_001346941.1. A RFP lentiviral vector was used as negative control. assay. U251 cells (3,000 cells/well) were seeded into 96-well plates in 100 µl complete medium. The CCK-8 (Dojindo Laboratories, Kumamoto, Japan) was used to measure cell viability accor ding to the manufacturer's instructions. The plates were incubated for 7 days. The number of viable cells was assessed by measurement of the spectrophotometric absorbance at 450 nm with a microplate reader iMARK (Bio-Rad Laboratories, Inc.).
Proliferation assay of U251 cells The Cell Counting
EdU assay. Cells that had undergone different interventions were seeded in 96-well plates at a density of 3x10 3 cells/well. EdU assay was done following manufacturer's instructions after culturing for 48 h Cell. The proliferation was assessed by calculating the percentage of EdU-positive cells in all cells.
Statistical analysis. Statistical analysis for TCGA was described above. SPSS software program (version 18.0; SPSS Inc., Chicago, IL, USA) and Graphpad Prism 5 software program (Graphpad Software, Inc., San Diego, CA, USA) were used for statistical analyses. All results were presented as mean ± standard deviation. The horizontal bars in histograms represented mean values. The one-way ANOVA was used to analyze the differences between groups for in vivo or in vitro studies. If the variance was homogeneous, Tukey's test was used for the post-hoc test; If not, Dunnett's test was used. P<0.05 was considered to indicate a statistically significant difference.
Results
Expression of CEP55 increased in human glioma cells and related to survival of patients with glioma.
CEP55 played an important role in proliferation of cells and overexpressed in several human tumors. The mRNA and protein of CEP55 were detected by qPCR and western blot analysis in 40 cases of glioma tissues and 10 cases of normal brain tissues. The mRNA of CEP55 in glioma tissues increased significantly than it in normal brain tissues (P<0.01) (Fig. 1A) . The result of western blot analysis showed that CEP55 proteins increased in 40 cases of glioma tissues accompany to improving of CEP55 mRNA. The level of CEP55 proteins in glioma was 7 times higher than it in normal brain tissues (P<0.001) (Fig. 1B and C) . There was overexpression of CEP55 in GBM U251 cells too, compared with normal brain tissues (Fig. 1A-C) . Our results of qPCR and western blot analysis confirmed that expression of CEP55 in glioma cells rocket up markedly than it in brain tissues.
To discover the value of CEP55 overexpression in glioma cells, we investigated the relationship of CEP55 expression and survival time in 663 cases of patients with glioma in The Cancer Genome Atlas (TCGA) database. The patients with glioma were classified to overexpression of CEP55 group (n=332) and low expression of CEP55 group (n=331) according to the threshold value (>=0.00226 and <0.00226) of CEP55 mRNA. The median overall survival (OS) of patients were 21.5 months in overexpression group and 107.1 months in low expression group. The result showed that expression of CEP55 was significantly associated to survival of patient with glioma and overexpression of CEP55 mean shorter survival time to patient with glioma (P<0.001) (Fig. 1D) .
Proliferation of U251 cells was suppressed by CEP55 RNAi.
CEP55 acted as a member of the centrosomal participated in mitosis of cell. Then, we supposed that expression of CEP55 was related to proliferation of glioma cells. To survey the effect of CEP55 on proliferation in glioma cells, the expression of CEP55 was knockdown with RNAi mediated by lentiviral vector in GBM U251 cells. The mRNA and protein of CEP55 in U251 cells decreased remarkably assayed by qPCR and western blot analysis after the cells infected by CEP55 siRNA lentiviral ( Fig. 2A and B) . The proliferation of three groups of U251 cells (control, NC and si-CEP55) were analyzed with CCK-8 kit and EdU. The result of CCK-8 showed that the proliferation of U251 cells with CEP55 knockdown dropped significantly than the cells without CEP55 intervened. The proliferation curve of U251 cells with CEP55 RNAi became flat similar to the medium (Fig. 2C ). There were 57.6 and 46.3% cells being reduplication phase separately in NC group and control group of U251 cells labeled with EdU. But only 6.72% cells were being proliferation phase in si-CEP55 group of U251 cells detected with flow cytometry. The rate of U251 cells being proliferation in si-CEP55 group was lower markedly than it in NC group and control group (Fig. 2D) . The result demonstrated that CEP55 RNAi was able to induce the inhibition of proliferation in U251 cells.
EGFRvIII promoted the proliferation and expression of CEP55 in U251 cells.
CEP55 is a conserved gene to preventing genetic damage and its protein acts as a regulator of cell cycle progression ensuring proper abscission, the final stage of cytokinesis (18) . Therefore, the expression of CEP55 might be regulated by other driver gene. The EGFRvIII is one frequent driver gene of GBM cells and plays an important role of proliferation in GBM cells. Then, EGFRvIII gene were transfected into U251 cells by lentiviral vector and the expression of EGFRvIII in U251 cells were detected with qPCR and Western-blot. The results of qPCR and western blot analysis verified that the mRNA and proteins of EGFRvIII increased significantly in U251 cells infected by EGFRvIII gene lentiviral vector compared with the cells infected by control lentiviral vector group (LVCON) and control group (Fig. 3A and B) . CCK-8 kit was used to analyze the proliferation of U251 cells after transduced with EGFRvIII gene. The results of curve showed that proliferation of U251 transduced with EGFRvIII gene increased considerably compared to the cells of LVCON group and control group (P<0.001) (Fig. 3C ). Expression of EGFRvIII was able to promote the proliferation of U251 cells.
Meanwhile, the qPCR and western blot analysis were performed to measuring the mRNA and protein of CEP55 in U251 cells transduced with EGFRvIII gene. The level of CEP55 mRNA was higher in U251 cells of EGFRvIII group than in cells of LVCON group and control group. After EGFRvIII gene transduced and expressed in U251 cells, the protein of CEP55 increased drastically compared to the cells of control group (Fig. 4A and B) . The results of qPCR and western blot analysis revealed that expression of EGFRvIII promoted the proliferation and expression of CEP55 in GBM U251 cells.
CEP55 RNAi inhibited the proliferation induced by EGFRvIII in U251 cells.
To detect the relationship of the proliferation promoted by EGFRvIII and expression of CEP55 in U251 cells, the expression of CEP55 was suppressed by RNAi in U251 cells transduced with EGFRvIII. The mRNA and protein of CEP55 assayed by qPCR and western blot analysis were reduced significantly in U251 cells with EGFRvIII overexpressing after it transduced with CEP55 siRNA (Fig. 5A and B) . The curve of growth was analyzed with CCK-8 in U251 cells with EGFRvIII overexpressing and CEP55 siRNA transduced. The results indicated that the proliferation of U251 cells declined markedly after the expression of CEP55 was inhibited by RNAi (Fig. 5C ). The proliferation of U251 cells with EGFRvIII overexpressing and CEP55 siRNA transduced was also measured by flow cytometry stained with EDU. The rate of proliferation in U251 cells expressing EGFRvIII declined to 4.82% after the expression of CEP55 was suppressed with CEP55 siRNA, and the rates of proliferation in U251 cells of NC group and control group were 62.5 and 56.7% respective ( Fig. 5D) . The result implied that the proliferation of U251 cells induced by EGFRvIII was inhibited by CEP55 RNAi and EGFRvIII promoted proliferation in U251 cells through regulating CEP55 overexpression. 
Discussion
CEP55 was known as a centrosome and midbody associated protein which might cooperate with members of endosomal sorting complex required for transport machinery to allow abscission (19, 20) . Soon after, overexpression of CEP55 was found in lung adenocarcinoma, gastric carcinoma and hepatocellular carcinoma, where it promote cell proliferation and invasion (17, 21, 22) . It was among the top 70 most highly overexpressed genes in an analysis across 12 cancer types including lung, lymphoma, medulloblastoma and breast, and was identified in prognostic signatures for these cancers (18, 23) . In this study, we found that CEP55 expression increased significantly in glioma and GBM U251 cells than in normal brain tissue. The level of CEP55 expression was significantly associated to survival of patient with glioma through analyzing CEP55 mRNA and survival in 663 patients from TCGA database. These results implied that CEP55 may play an important role on proliferation or invasion of glioma cells. To observe the effect of CEP55 overexpression on glioma cells, expression of CEP55 were inhibited by RNAi in GBM U251 cells in this study. The proliferation of U251 cells was markedly suppressed after CEP55 knockdown. This result was confirmed in Wang et al study, which provided evidence of inhibiting cell proliferation and inducing cell apoptosis by knockdown of CEP55 in glioma cells (24) .
CEP55 expresses in various cancers and is barely detectable in normal tissues except for testis and thymus (24) . Its overexpression and activation was regulated via aberrantly upregulated PI3K/AKT pathways and Forkhead box protein M1 in lung cancer, hepatocellular carcinoma and head-neck squamous cell carcinoma (17, 21, 25) . In glioma, the EGFR and its mutations contributed to tumorigenesis and biology via various ways. EGFR amplification and mutation were highly frequent genetic change in gliomas, which resulted in expression of EGFRvIII and overexpression of EGFR. Several studies demonstrated that they were associated with proliferation, progression, and chemo-radiotherapy resistance of gliomas (5) (6) (7) (8) (9) . The PI3K/AKT pathway activated by EGFR and EGFRvIII was an important molecular mechanism which gave rise to promoting proliferation and resistance of drug and radiation (9, 26) . Both EGFR/EGFRvIII and CEP55 were associated with proliferation of glioma cells and activation of PI3K/AKT pathway. What is the relationship between CEP55 and EGFR, especially EGFRvIII which is a ligand-independent constitutively active variant of EGFR, in regulation of glioma cells proliferation? To investigate the regulating mechanism of proliferation by EGFRvIII and CEP55 in glioma cells, U251 cells were firstly transfected with EGFRvIII gene in this study. Expression of EGFRvIII promoted significantly the proliferation of U251 cells transfected with EGFRvIII gene. Meanwhile, the CEP55 expression increased remarkably in U251 cells expressing EGFRvIII compared with cells of control group. This result suggested that CEP55 participated the regulating mechanism of proliferation induced by EGFRvIII in U251 cells.
EGFRvIII, a mutant of EGFR, was able to over-activate various downstream signaling pathways, including the PI3K/AKT and RAS-RAF-ERK and regulated many biological outputs that are beneficial to glioma cell proliferation including their initiation and progression of cell cycle (27) . CEP55 participated directly abscission in mitosis of cell. To verify CEP55 mediating the proliferation of U251 cells promoted by EGFRvIII, the expression of CEP55 was inhibited by CEP55 siRNA in U251 cell with EGFRvIII transfecting. The proliferation of U251 cells promoted by EGFRvIII declined significantly after CEP55 was knockdown. These results demonstrated that CEP55 participated the proliferation regulated by EGFRvIII and knockdown CEP55 was able to eliminate the effect of promoting proliferation induced by EGFRvIII in U251 cells. Certainly, CEP55 is a mitotic phosphoprotein, acting as an effector of proliferation pathways, which required tightly precise regulation in cytokinesis. The effect of deregulated CEP55 expression in the glioma cells on upstream factor of regulating proliferation such as EGFR remain unresolved. The molecular mechanism and pathways of EGFRvIII upregulating CEP55 expression in detail need further research in our future study.
In conclusion, in this study, we found that CEP55 overexpression played a key role in proliferation of glioma cells and mediated EGFRvIII stimulating proliferation in glioma cells. Knockdown of CEP55 inhibited proliferation of U251 cells induced by EGFRvIII and CEP55 may be a novel molecular therapeutic target to patients with gliomas expressing EGFRvIII. The mechanism underlying proliferation regulated by EGFRvIII-CEP55 in glioma cells need further investigation.
